Engaging Innovation | Friends of Cancer Research

Engaging Innovation

Featured Post

January 7, 2020

Senate Briefing - Turning the Tables: Innovator Meets Regulator

At a Senate briefing hosted by Friends of Cancer Research (Friends), a panel comprised of leading stakeholders convened to discuss changes in cancer care and criticisms of the U.S. Food and Drug Administration’s (FDA) expedited approval programs. As recent advancements to discover and develop targeted therapies, immunomodulating agents, and cell-based...
More Posts

Recent Posts

No Results With Current Filter Choices

Friends Of Cancer Research Annual Meeting 2019

The Friends of Cancer Research (Friends) Annual Meeting 2019 began with welcoming remarks by Ellen Sigal, Chairperson & Founder of Friends, and Jeff Allen, President & CEO of Friends. In her remarks, Sigal emphasized the time and effort spent by working group members on putting together collaborative whitepapers meant to...

BioPharma Congress V

On Monday, October 7, 2019, Friends of Cancer Research (Friends) and Prevision Policy hosted the fifth annual BioPharma Congress. This year’s event focused on gene therapies, approval standards, new payment models, drug pricing, and the future of the U.S. Food & Drug Administration (FDA). Featured speakers included Assistant to the...

Despite criticism, FDA is doing what is right by rare cancer patients

On October 1, the first-ever Rare Cancer Day, an awareness day highlighting the challenges people living with rare cancers face and emphasizing the importance of early diagnosis, was marked by thousands nationwide. Cancer is not a singular disease but, rather, many diseases, of which several are rare. One in 5...

8th Blueprint for Breakthrough: Validating Real-World Endpoints for an Evolving Regulatory Landscape

  "Real-World Evidence is already here." - Ned Sharpless, Acting FDA Commissioner On September 18, 2019, Friends of Cancer Research (Friends) and Alexandria Real Estate Equities, Inc. hosted a meeting to present data from the Real-World Evidence (RWE) Pilot 2.0, building on the Friends RWE Pilot 1.0. The meeting focused on the...

Real-World Evidence Roundtable

Friends of Cancer Research (Friends) convened a roundtable meeting on February 6, 2019, to identify key challenges and next steps to further characterize how real-world evidence (RWE) can fill evidence gaps about the performance of approved agents used in the real-world setting, including in populations that may not have been...

Designing the Future of Cell Therapies

“Patients are waiting. These therapies are potentially curative. They’re important for the field.” - Ellen Sigal   On May 17, 2019, Friends of Cancer Research (Friends) and the Parker Institute for Cancer Immunotherapy (PICI) held a public meeting on “Designing the Future of Cell Therapies” to explore forward-looking opportunities in the cell...

Data Driven: How Oncologists Perceive FDA-Approved Drug Labeling Compared to Other Major Prescribing Resources

Physicians rely on a variety of sources of information to provide high-quality care to patients. In oncology, some of the most prominent resources that inform provider decision-making are the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) clinical practice guidelines; drug compendia; electronic point-of-care decision...
first
prev
1
2
3
4
5
6
7
next
last
Back to Top